1. Scrip
  3. >>Clinical Trials

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Filing Expected Before Year-End

 
• By Andrew McConaghie

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

AZ_China
AstraZeneca's operations in China, where roxodustat is already approved • Source: AstraZeneca

AstraZeneca PLC and FibroGen Inc. will be confident of US approval for roxadustat after unveiling reassuring cardiovascular safety data for their new anemia treatment.

Roxadustat is the front runner in a new class of oral HIF-PH inhibitors used to treat anemia, and needed to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D